Molecular imaging and radionuclide therapy · 2026
Diagnostic Value of 68Ga-FAPI PET/CT Versus 18F-FDG PET/CT in Laryngeal Cancer Staging.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kalender Ebuzer, Ekinci Yıldırım Edanur, Eren Buket, Elboğa Umut, Şahin Ertan
Аннотация
OBJECTIVE: To investigate whether gallium-68 fibroblast activation protein inhibitor positron emission tomography/computed tomography 68Ga-FAPI PET/CT is superior to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG) PET/CT in the staging of patients with laryngeal cancer (LC).
METHODS: A total of 14 patients diagnosed with LC were retrospectively included in the study, of whom 13 were male and 1 female, with a mean age of 65 years. All participants were initially referred to our department for staging with 18F-FDG PET/CT. Subsequently, each patient underwent a 68Ga-FAPI PET/CT scan three days following the 18F-FDG PET/CT. Both sets of imaging studies were independently evaluated by two experienced nuclear medicine physicians, and the findings were systematicaly compared to assess potential differences in diagnostic performance.
RESULTS: The median maximum standard uptake values (SUVmax) of primary tumors was significantly higher in 68Ga-FAPI PET/CT 10.95; range: 3.5-19.2) compared to 18F-FDG PET/CT (4.85; range: 2.2-10.9). Lymph node involvement was observed on FDG scans in 3 patients, in ipsilateral levels 2 and/or 3, with a median SUVmax of 3.7 (range: 2.4-4.1). FAPI PET/CT also detected lymph node involvement at the same levels in 3 patients, with a notably higher SUVmax of 7.9 (range: 6.8-10.4).
CONCLUSION: In this study, our results suggest that 68Ga-FAPI PET/CT demonstrates superior radiotracer uptake in both primary tumors and lymph nodes, which may enhance detection sensitivity for LC staging compared with 18F-FDG PET/CT. Nevertheless, further prospective studies with larger patient populations are warranted to validate these preliminary observations and determine the clinical value of this emerging imaging modality.
METHODS: A total of 14 patients diagnosed with LC were retrospectively included in the study, of whom 13 were male and 1 female, with a mean age of 65 years. All participants were initially referred to our department for staging with 18F-FDG PET/CT. Subsequently, each patient underwent a 68Ga-FAPI PET/CT scan three days following the 18F-FDG PET/CT. Both sets of imaging studies were independently evaluated by two experienced nuclear medicine physicians, and the findings were systematicaly compared to assess potential differences in diagnostic performance.
RESULTS: The median maximum standard uptake values (SUVmax) of primary tumors was significantly higher in 68Ga-FAPI PET/CT 10.95; range: 3.5-19.2) compared to 18F-FDG PET/CT (4.85; range: 2.2-10.9). Lymph node involvement was observed on FDG scans in 3 patients, in ipsilateral levels 2 and/or 3, with a median SUVmax of 3.7 (range: 2.4-4.1). FAPI PET/CT also detected lymph node involvement at the same levels in 3 patients, with a notably higher SUVmax of 7.9 (range: 6.8-10.4).
CONCLUSION: In this study, our results suggest that 68Ga-FAPI PET/CT demonstrates superior radiotracer uptake in both primary tumors and lymph nodes, which may enhance detection sensitivity for LC staging compared with 18F-FDG PET/CT. Nevertheless, further prospective studies with larger patient populations are warranted to validate these preliminary observations and determine the clinical value of this emerging imaging modality.